摘要
目的研究急性心肌梗死(AMI)患者术中使用国产盐酸替罗非班的有效性和安全性。方法入选156例接受急诊经皮冠状动脉介入治疗(PCI)的ST段抬高急性心肌梗死(STEMI)患者,给予替罗非班静脉持续泵入至术后12～48h,观察30d内的主要不良心脏事件(MACE)的发生率和左室射血分数(LVEF)。结果安全性及预后:术后30d内MACE发生率:死亡0例,再梗死1例(0.625%),LVEF(%):(59±8)%,所有患者均未发生严重出血,轻度出血6.3%,主要是术后伤口渗血、穿刺处血肿,均经对症处理好转。结论盐酸替罗非班能显著改善左室射血分数,使术后30dMACE发生率降低,同时并不显著增加出血并发症的发生率。
Objective This study was to investigate the clinical outcomes and safety of PCI combined with tirofiban therapy in patients with AMI.Methods To selected 156 cases of patients with acute STEMI who receive PCI,tirofiban was given continuously intravenous infusion to postoperative 12-48h,observed the major adverse cardiac events（MACE）and left ventricular ejection fraction （LVEF）at 30 days after operation.Results Safety and prognosis：the incidence of MACE in 30 days：death （cases）0,re-infarction （cases）1 （0.625%）LVEF （%）59±8%,none of the patient with serious bleeding,hyporrhea 6.3%,the postoperative wound exudation and hematoma have been improved with symptomatic treatment.Conclusion Tirofiban can significantly improve left ventricular ejection fraction,so that to reduce the incidence of MACE in 30 days,while not to increase the incidence of bleeding complications.
出处
《实用心脑肺血管病杂志》
2009年第12期1050-1051,共2页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
关键词
冠状动脉疾病
心肌梗塞
介入治疗
替罗非班
Coronary disease
Myocardial infarction
Percutaneous coronary intervention
Tirofiban
